TY - JOUR UR - https://doi.org/10.3389/fnagi.2022.899158 Y1 - 2022/06/20/ ID - discovery10153042 N1 - This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ TI - Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer's Clinical Continuum VL - 14 JF - Frontiers in Aging Neuroscience PB - FRONTIERS MEDIA SA KW - Science & Technology KW - Life Sciences & Biomedicine KW - Geriatrics & Gerontology KW - Neurosciences KW - Neurosciences & Neurology KW - Alzheimer's disease KW - amyloid deposition KW - cognition KW - depressive symptoms KW - anxiety KW - glucose metabolism KW - subjective cognitive decline KW - gray matter KW - MILD COGNITIVE IMPAIRMENT KW - POSITRON-EMISSION-TOMOGRAPHY KW - SUBJECTIVE MEMORY COMPLAINTS KW - CORTICAL AMYLOID DEPOSITION KW - QUALITY-OF-LIFE KW - NEUROPSYCHIATRIC SYMPTOMS KW - OLDER-ADULTS KW - MATTER HYPOMETABOLISM KW - PSYCHIATRIC-SYMPTOMS KW - BEHAVIORAL SYMPTOMS N2 - Background: Depressive and anxiety symptoms are frequent in Alzheimer?s disease and associated with increased risk of developing Alzheimer?s disease in older adults. We sought to examine their relationships to Alzheimer?s disease biomarkers across the preclinical and clinical stages of the disease. Method: Fifty-six healthy controls, 35 patients with subjective cognitive decline and 56 amyloid-positive cognitively impaired patients on the Alzheimer?s continuum completed depression and anxiety questionnaires, neuropsychological tests and neuroimaging assessments. We performed multiple regressions in each group separately to assess within group associations of depressive and anxiety symptoms with either cognition (global cognition and episodic memory) or neuroimaging data (gray matter volume, glucose metabolism and amyloid load). Results: Depressive symptoms, but not anxiety, were higher in patients with subjective cognitive decline and cognitively impaired patients on the Alzheimer?s continuum compared to healthy controls. Greater depressive symptoms were associated with higher amyloid load in subjective cognitive decline patients, while they were related to higher cognition and glucose metabolism, and to better awareness of cognitive difficulties, in cognitively impaired patients on the Alzheimer?s continuum. In contrast, anxiety symptoms were not associated with brain integrity in any group. Conclusion: These data show that more depressive symptoms are associated with greater Alzheimer?s disease biomarkers in subjective cognitive decline patients, while they reflect better cognitive deficit awareness in cognitively impaired patients on the Alzheimer?s continuum. Our findings highlight the relevance of assessing and treating depressive symptoms in the preclinical stages of Alzheimer?s disease. A1 - Moulinet, Ines A1 - Touron, Edelweiss A1 - Mezenge, Florence A1 - Dautricourt, Sophie A1 - de la Sayette, Vincent A1 - Vivien, Denis A1 - Marchant, Natalie L A1 - Poisnel, Geraldine A1 - Chetelat, Gael EP - 12 AV - public ER -